Bioventus Inc.

NASDAQ: BVS · Real-Time Price · USD
7.39
0.05 (0.68%)
At close: Aug 15, 2025, 12:43 PM

Bioventus Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
573.28M 512.35M 512.12M 430.9M
Cost of Revenue
185.05M 184.15M 181.04M 128.19M
Gross Profit
388.23M 328.19M 331.08M 302.71M
Operating Income
-11.98M -81.72M -167.23M 12.06M
Interest Income
n/a n/a n/a n/a
Pretax Income
-49.13M -121.11M -189.03M 9.49M
Net Income
-33.54M -156.23M -158.7M 19.38M
Selling & General & Admin
340.89M 303.88M 332.13M 254.25M
Research & Development
13.64M 13.45M 23.85M 19.04M
Other Expenses
45.67M 92.59M 142.33M 17.35M
Operating Expenses
400.2M 409.92M 498.31M 290.64M
Interest Expense
38.79M 40.68M 12.02M 1.11M
Selling & Marketing Expenses
n/a 3.85M 5.2M 3.87M
Cost & Expenses
585.26M 594.07M 679.35M 418.84M
Income Tax Expense
-5.29M 85K -44.37M -1.97M
Shares Outstanding (Basic)
65.36M 62.65M 61.39M 45.47M
Shares Outstanding (Diluted)
65.36M 62.65M 61.39M 45.47M
EPS (Basic)
-0.75 -2.49 -2.59 -0.15
EPS (Diluted)
-0.75 -2.49 -2.59 -0.15
EBITDA
-49.55M -23.07M -121.61M 45.48M
EBIT
-10.33M -80.44M -177M 10.6M
Depreciation & Amortization
49.55M 57.37M 55.4M 38.68M